Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01364571 · ClinicalTrials.gov registry record · Phase 1
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 456
- Enrollment target
NCT01364571: Completed Phase 1 study, sponsored by Pfizer.
NCT01364571 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 456 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (660% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01364571, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 456 participants
- Enrollment target
Study Summary
This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune response elicited by the vaccine in healthy adults aged 18 to \<65 years. In addition, the study aims to assess the effect of the SA4Ag vaccine on the presence of the Staphylococcus aureus on the skin and within the nose, throat and perineum of healthy adults aged 18 to \<65 years.
Interventions
- PROCEDURE Blood draw
- PROCEDURE Blood sample
- BIOLOGICAL SA4Ag vaccine low dose
- PROCEDURE Colonization swab sample
- BIOLOGICAL SA4Ag vaccine mid dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
What the finished NCT01364571 record still lists
NCT01364571 is an interventional study that assigns participants to a tested intervention. The registered 456 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (660% higher).
The record links to 0 conditions, and to 5 interventions - of which Blood draw is the first listed.
NCT01364571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01364571 about?
NCT01364571 is a clinical study titled "Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years". This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune resp...
What is the current status of trial NCT01364571?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 456 participants. The study started on 2011-08. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01364571?
The interventions under investigation include: Blood draw (PROCEDURE), Blood sample (PROCEDURE), SA4Ag vaccine low dose (BIOLOGICAL), Colonization swab sample (PROCEDURE), SA4Ag vaccine mid dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT01364571?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01364571's enrollment target sits among peer trials
456 54th of 2000 higher than 1,947 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04462302 · 456 participants · NA
An Internet-based Program to Help Cancer Survivors Manage Pain
- NCT05820919 · 456 participants · NA
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
- NCT06254612 · 456 participants · Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
- NCT06457841 · 456 participants · NA
Stress and Resilience
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia